Drugs / ENV-294
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07336940 | Sep 2025 → Jan 2026 | atopic eczema | Enveda Therapeutics | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07643766 | Jun 2026 → Dec 2027 expected | atopic eczema | Enveda Therapeutics | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07301255 | Jan → Dec 2026 expected | asthma | Enveda Therapeutics | Recruiting | No outcome recorded |
| Phase 2 | NCT07298395 | Dec 2025 → Dec 2026 expected | atopic eczema | Enveda Therapeutics | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-07-23 | Enveda Therapeutics | Results Enveda’s Positive Phase 1B Results for ENV-294, a Potential First-in-Class Oral Therapy for Moderate-to-Severe Atopic Dermatitis, Were Presented at AAD Innovation Academy; Additional Details to Be Shared at EADV enveda.com ↗
In the Phase 1b study, which was designed with a primary objective of evaluating safety, 28 days of once-daily ENV-294 was associated with improvements across the study’s exploratory efficacy endpoints with a generally well-tolerated safety profile. |
| 2026-03-31 | Enveda Therapeutics | Results Enveda Reports Positive Results for ENV-294 in a Phase 1b Clinical Trial of Patients with Moderate-to-Severe Atopic Dermatitis enveda.com ↗ |
| 2025-05-28 | Enveda Therapeutics | Results Enveda Reports Favorable Phase 1 Safety for Novel Oral Anti-Inflammatory, Launches Phase 1b Trial in Atopic Dermatitis enveda.com ↗
Based on the favorable safety and tolerability results in healthy volunteers, the Safety Review Committee endorsed advancement to a Phase 1b clinical trial evaluating ENV-294 in patients with atopic dermatitis. |
All press releases naming this drug 6 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ENV-294 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07301255 ↗ |
| Route | Oral | “ENV-294 is an orally administered investigational drug supplied as tablets.” NCT07298395 ↗ |